{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:40:58Z","timestamp":1780432858494,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00198-026-07936-4","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:11:45Z","timestamp":1772784705000},"page":"983-989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world rebound pattern of serum collagen type I C-telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment-induced bone loss"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3965-5295","authenticated-orcid":false,"given":"Federico","family":"Aldegheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-232X","authenticated-orcid":false,"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5134-1304","authenticated-orcid":false,"given":"Matteo","family":"Appoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Rotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ruzzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bertelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0755","authenticated-orcid":false,"given":"Giovanni","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7471-3076","authenticated-orcid":false,"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-2293","authenticated-orcid":false,"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-5655","authenticated-orcid":false,"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"7936_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.11005\/jbm.2022.29.2.93","volume":"29","author":"SH Kong","year":"2022","unstructured":"Kong SH, Kim JH, Kim SW, Jeong AJ, Lee S-H, Ye S-K (2022) Effect of denosumab on the change of osteoclast precursors compared to zoledronate treatment in postmenopausal women with osteoporosis. J Bone Metab 29:93\u2013101. https:\/\/doi.org\/10.11005\/jbm.2022.29.2.93","journal-title":"J Bone Metab"},{"key":"7936_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-025-02991-z","volume":"37","author":"O Lamy","year":"2025","unstructured":"Lamy O, Everts-Graber J, Rodriguez EG (2025) Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach. Aging Clin Exp Res 37:70. https:\/\/doi.org\/10.1007\/s40520-025-02991-z","journal-title":"Aging Clin Exp Res"},{"key":"7936_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"7936_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115478","volume":"138","author":"P Makras","year":"2020","unstructured":"P Makras SE Papapoulos SA Polyzos NM Appelman-Dijkstra AD Anastasilakis 2020 The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis Bone 138 115478. https:\/\/doi.org\/10.1016\/j.bone.2020.115478","journal-title":"Bone"},{"key":"7936_CR5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"AS S\u00f8lling T Harsl\u00f8f B Langdahl 2021 Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study J Bone Miner Res 36 1245 1254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Miner Res"},{"key":"7936_CR6","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","volume":"109","author":"G Grassi","year":"2024","unstructured":"Grassi G, Ghielmetti A, Zampogna M, Chiodini I, Arosio M, Mantovani G (2024) Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion? J Clin Endocrinol Metab 109:e1817\u2013e1826. https:\/\/doi.org\/10.1210\/clinem\/dgae224","journal-title":"J Clin Endocrinol Metab"},{"key":"7936_CR7","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2020","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O (2020) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36:1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335","journal-title":"J Bone Miner Res"},{"key":"7936_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","volume":"36","author":"N Laursen","year":"2025","unstructured":"Laursen N, S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2025) Clinical experience with denosumab discontinuation. Osteoporos Int 36:435\u2013446. https:\/\/doi.org\/10.1007\/s00198-024-07351-7","journal-title":"Osteoporos Int"},{"key":"7936_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19:307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"key":"7936_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2019.03.019","volume":"123","author":"A Fassio","year":"2019","unstructured":"Fassio A, Adami G, Benini C, Vantaggiato E, Saag KG, Giollo A (2019) Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone 123:191\u2013195. https:\/\/doi.org\/10.1016\/j.bone.2019.03.019","journal-title":"Bone"},{"key":"7936_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jbmr\/zjae170","volume":"40","author":"M Schini","year":"2025","unstructured":"Schini M, Gossiel F, Saini T, Banda P, Ward R, Vilaca T (2025) The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation. J Bone Miner Res 40:301\u2013306. https:\/\/doi.org\/10.1093\/jbmr\/zjae170","journal-title":"J Bone Miner Res"},{"key":"7936_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/jbmr\/zjaf037","volume":"40","author":"S Kumar","year":"2025","unstructured":"Kumar S, Wang M, Kim AS, Center JR, McDonald MM, Girgis CM (2025) Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. J Bone Miner Res 40:1017\u20131034. https:\/\/doi.org\/10.1093\/jbmr\/zjaf037","journal-title":"J Bone Miner Res"},{"key":"7936_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40778-025-00252-3","volume":"11","author":"A Rajamohanan","year":"2025","unstructured":"Rajamohanan A, Jalaja A, Nair A (2025) Denosumab withdrawal and rebound bone resorption: molecular mechanisms and approaches for treatment. Curr Stem Cell Rep 11:10. https:\/\/doi.org\/10.1007\/s40778-025-00252-3","journal-title":"Curr Stem Cell Rep"},{"key":"7936_CR14","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2020","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2020) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res 37:2112\u20132120. https:\/\/doi.org\/10.1002\/jbmr.4705","journal-title":"J Bone Miner Res"},{"key":"7936_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u2013443. https:\/\/doi.org\/10.1016\/S0140-6736(15)60995-3","journal-title":"Lancet"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07936-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:26:41Z","timestamp":1779290801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-07936-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7936"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07936-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the protocol 1483CESC approved by our local Ethics Committee, in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was collected for each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients provided consent for publication of anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.R. declares speaker fees from Accord and GSK outside the submitted work.O.V. declares advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Ely-Lilly, UCB, AbbVie, MSD, and BMS outside the submitted work.M.R. reports advisory board honoraria, consultancy fees, and\/or speaker fees from AbbVie, Eli-Lilly, ItalFarmaco, Neopharmed-Gentili, Theramex, Janssen-Cilag, and UCB, outside the submitted work.G. A. has received advisory board honoraria, consultancy fees, and\/or speaker fees from Theramex, UCB, Lilly, Galapagos, Fresenius Kabi, Amgen, BMS, Abiogen, and Pfizer.D.G. declares advisory board honoraria, consultancy fees, and\/or speaker fees from Abiogen, Celgene, Eli-Lilly, Neopharmed-Gentili, Pfizer, and UCB outside the submitted work.A.F. has received advisory board honoraria, consultancy fees, and\/or speaker fees from Boehringer Ingelheim and UCB Pharma, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}